Effects of chronic combined treatment with captopril and pravastatin on the progression of insulin resistance and cardiovascular alterations in an experimental model of obesity in dogs

American Journal of Hypertension

Volumn 11, Issue 7, 1998, Pages 844-851

  Villa, Eduardo ^a   Rábano, Alberto ^a   Albarrán, Olga G ^a   Ruilope, Luis M ^a   García Robles, Rafael ^a,b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Beagle dogs; Captopril; Insulin resistance; Obesity; Pravastatin; Vascular hypertrophy

Indexed keywords

CAPTOPRIL; PRAVASTATIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DOG; HEART HYPERTROPHY; HEART PROTECTION; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; MALE; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; VASCULAR DISEASE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CAPTOPRIL; CARDIOVASCULAR DISEASES; CHOLESTEROL; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOGS; DRUG THERAPY, COMBINATION; HEART; INSULIN; INSULIN RESISTANCE; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIUM; OBESITY; PRAVASTATIN; TRIGLYCERIDES;

EID: 0032126272     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00053-3     Document Type: Article

References (38)

1. 1. Steinberg HO, Chaker H, Leaming R, et al: Obesity/ insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601-2610.
2. 2. Rocchini AP, Wilson RF, Marker P, et al: Metabolic and hemodynamic effects of a graded intracoronary insulin infusion in normal and fat anesthetized dogs. A preliminary study. Hypertension 1996;27:354-359.
3. 3. Kannel WB, Castelli WP, Gordon T, et al: Serum cholesterol, lipoproteins, and the risk of coronary heart disease: The Framingham Study. Ann Intern Med 1971; 74:1-12.
4. 4. LaRosa JC, Hunninghake D, Bush D, et al: The cholesterol facts: serum cholesterol, and coronary heart disease: Circulation 1990;81:1721-1733.
5. 5. Kannel W, Brand N, Skinner J, et al: Relation of adiposity to blood pressure and development of hypertension: The Framingham Study. Ann Int Med 1967;67:48-59.
6. 6. Stamler R, Stamler J, Riedlinger WE, et al: Weight and blood pressure: findings in hypertension screening in one million Americans. JAMA 1978;240:1607-1610.
7. 7. Kaplan NM: Effects of antihypertensive therapy on insulin resistance. Hypertension 1992;19(suppl):I116-I118.
8. 8. Lind L, Pollare T, Berne C, et al: Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994;128: 1177-1183.
9. 9. Rocchini AP, Moorehead CP, DeRemer S, et al: Pathogenesis of weight-related changes in blood pressure in dogs. Hypertension 1989;13:922-928.
10. 10. Robles RG, Villa E, Santirso R, et al: Effects of Captopril on sympathetic activity lipid and carbohydrate metabolism in a model of obesity-induced hypertension in dogs. Am J Hypertens 1993;6:1009-1015.
11. 11. Villa E, Martínez J, Ruilope LM, et al: Cicaprost, a prostacyclin analog, protects renal function in uninephrectomized dogs in the absence of changes in blood pressure. Am J Hypertens 1993;6:253-257.
12. 12. Shen DC, Shieh SM, Fuh MM, et al: Resistance to insulin-stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988;66:580-583.
13. 13. Haidet GC, Wennberg PW, Rector TS: Aging and vasoreactivity: in vivo responses in the beagle hindlimb. Am J Physiol 1995;268:H92-H99.
14. 14. Sowers JR, Standley PR, Ram JL, et al: Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens 1993;6(suppl):260S-270S.
15. 15. Stout RW: Insulin as a mitogenic growth factor: role in the pathogenesis of cardiovascular disease. Am J Med 1991;90(suppl 2A):62S-65S.
16. 16. Decker RS, Cook MG, Behnke-Barclay M, et al: Some growth factors stimulate cultured adult rabbit ventricular myocyte hypertrophy in the absence of mechanical loading. Circ Res 1995;77:544-555.
17. 17. Weber H, Taylor DS, Molloy CJ: Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin. J Clin Invest 1994;93:788-798.
18. 18. Griffin SA, Brown WCB, MacPherson F, et al: Angiotensin II causes vascular hypertrophy in part by a nonpressor mechanism. Hypertension 1991;17:626-635.
19. 19. Baker KM, Aceto JF: Angiotensin II stimulation of protein synthesis and protein growth in chick heart cells. Am J Physiol 1990;259:H610-H618.
20. 1 receptor. Am J Hypertens 1992;5:276-280.
21. 21. Blaes N, Boissel JP: Growth-stimulating effect of catecholamines in rat aortic smooth muscle cells in culture. J Cell Physiol 1983;116:167-172.
22. 22. Adams MA, Bobik A, Korner PI: Differential development of vascular and cardiac hypertrophy in genetic hypertension. Relation to sympathetic function. Hypertension 1989;14:191-202.
23. 23. Korner P, Bobik A, Oddie C, et al: Sympathoadrenal system is critical for structural changes in genetic hypertension. Hypertension 1993;22:243-252.
24. 24. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-873.
25. 25. Chan P, Tomlinsom B, Lee CB, et al: Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects. Hypertension 1996;28:647-651.
26. 26. LaRosa: Cholesterol lowering, low cholesterol and mortality. Am J Cardiol 1993;72:776-786.
27. 27. Gariepy J, Simon A, Massonneau M, et al: Echographic assessment of carotid and femoral arterial structure in men with essential hypertension. Group PCVMETRA. Am J Hypertens 1996;9:126-136.
28. 28. Shiomi M, Ito T, Shiraishi M, et al: Inheritability of atherosclerosis and the role of lipoproteins as risk factors in the development of atherosclerosis in WHHL rabbits: risk factors related to coronary atherosclerosis are different for those related to aortic atherosclerosis. Atherosclerosis 1992;96:43-52.
29. 29. Suzuki M, Shinozaki K, Kanazawa A, et al: Insulin resistance as an independent risk factor for carotid wall thickening. Hypertension 1996;28:593-598.
30. 30. Creager MA, Cooke JP, Mendelsohn MP, et al: Impaired vasodilation of forearm resistance vessel in hypercholesterolemic humans. J Clin Invest 1990;86:228-234.
31. 31. Gilligan DM, Guetta V, Panza JA, et al: Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994;90:35-41.
32. 32. Creager MA, Gallagher SJ, Girerd XJ, et al: L-Arginine improves endothelial-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-1253.
33. 33. Casino PR, Kilcoyne CM, Quyyumi AA, et al: The role of nitric oxide in the endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993; 88:2541-2547.
34. 34. Egashira K, Hirooka Y, Kai H, et al: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-2524.
35. 35. Harrison DG, Armstrong ML, Freiman PC, et al: Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987;80: 1808-1811.
36. 36. Leung WH, Lau CP, Wong CK: Beeficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993;341:1496-1500.
37. 37. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
38. 38. Shepherd J, Stuart MC, Ford I, et al, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333: 1301-1307.